Janssen (J&J) Resumed

After a thorough safety review, the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) have determined that the use of Janssen (J&J) COVID vaccine should resume in the United States. As such, the Georgia Department of Public Health (DPH) COVID Vaccine Program will again offer J&J vaccine to Georgians aged 18 and older.

A warning will be added to the J&J vaccine about the potential for very rare, but severe blood clots associated with the vaccine. Vaccine providers administering the J&J vaccine should review the Janssen COVID-19 Vaccine Fact Sheet. Vaccine recipients and/or their caregivers should be provided with the Janssen COVID-19 Vaccine Fact Sheet for Recipients and Caregivers. Both fact sheets now include information about thrombosis and thrombocytopenia syndrome which have occurred in a very small number of people who have received the J&J vaccine.

The FDA and CDC have confidence that J&J vaccine is safe and effective in preventing COVID-19, and that its known and potential benefits outweigh its known and potential risks. The chance of these serious, sometimes fatal, adverse events occurring is very low.

Health departments throughout South Health District will resume using Janssen vaccine Tuesday, April 27. To schedule an appointment, call 844-955-1499.